{
  "DOI": "10.1038/s41431-023-01507-5",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/s41431-023-01507-5",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eHereditary Breast and Ovarian Cancer (HBOC) is a genetic condition associated with increased risk of cancers. The past decade has brought about significant changes to hereditary breast and ovarian cancer (HBOC) diagnostic testing with new treatments, testing methods and strategies, and evolving information on genetic associations. These best practice guidelines have been produced to assist clinical laboratories in effectively addressing the complexities of HBOC testing, while taking into account advancements since the last guidelines were published in 2007. These guidelines summarise cancer risk data from recent studies for the most commonly tested high and moderate risk HBOC genes for laboratories to refer to as a guide. Furthermore, recommendations are provided for somatic and germline testing services with regards to clinical referral, laboratory analyses, variant interpretation, and reporting. The guidelines present recommendations where ‘\u003cjats:bold\u003emust\u003c/jats:bold\u003e’ is assigned to advocate that the recommendation is essential; and ‘\u003cjats:bold\u003eshould\u003c/jats:bold\u003e’ is assigned to advocate that the recommendation is highly advised but may not be universally applicable. Recommendations are presented in the form of shaded italicised statements throughout the document, and in the form of a table in supplementary materials (Table S4). Finally, for the purposes of encouraging standardisation and aiding implementation of recommendations, example report wording covering the essential points to be included is provided for the most common HBOC referral and reporting scenarios. These guidelines are aimed primarily at genomic scientists working in diagnostic testing laboratories.\u003c/jats:p\u003e",
  "alternative-id": [
    "1507"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "8 June 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "7 November 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "21 November 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "5 March 2024"
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1,
      "value": "The authors declare no competing interests."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0009-0008-2425-5194",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "McDevitt",
      "given": "Trudi",
      "sequence": "first"
    },
    {
      "ORCID": "http://orcid.org/0000-0001-7071-7048",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Durkie",
      "given": "Miranda",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Arnold",
      "given": "Norbert",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0001-9360-8194",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Burghel",
      "given": "George J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Butler",
      "given": "Samantha",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-0841-7372",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Claes",
      "given": "Kathleen B. M.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Logan",
      "given": "Peter",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Robinson",
      "given": "Rachel",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-1649-1495",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Sheils",
      "given": "Katie",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Wolstenholme",
      "given": "Nicola",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-3303-8713",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Hanson",
      "given": "Helen",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Turnbull",
      "given": "Clare",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-3217-3032",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Hume",
      "given": "Stacey",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2024,
        3,
        5
      ]
    ],
    "date-time": "2024-03-05T07:02:01Z",
    "timestamp": 1709622121000
  },
  "deposited": {
    "date-parts": [
      [
        2024,
        3,
        5
      ]
    ],
    "date-time": "2024-03-05T07:02:48Z",
    "timestamp": 1709622168000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        5,
        1
      ]
    ],
    "date-time": "2024-05-01T00:46:52Z",
    "timestamp": 1714524412587
  },
  "is-referenced-by-count": 1,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issued": {
    "date-parts": [
      [
        2024,
        3,
        5
      ]
    ]
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2024,
            3,
            5
          ]
        ],
        "date-time": "2024-03-05T00:00:00Z",
        "timestamp": 1709596800000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2024,
            3,
            5
          ]
        ],
        "date-time": "2024-03-05T00:00:00Z",
        "timestamp": 1709596800000
      }
    }
  ],
  "link": [
    {
      "URL": "https://www.nature.com/articles/s41431-023-01507-5.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41431-023-01507-5",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41431-023-01507-5.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2024,
        3,
        5
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2024,
        3,
        5
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.3322/caac.21492",
      "author": "F Bray",
      "doi-asserted-by": "publisher",
      "first-page": "394",
      "journal-title": "CA Cancer J Clin",
      "key": "1507_CR1",
      "unstructured": "Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.",
      "volume": "68",
      "year": "2018"
    },
    {
      "DOI": "10.1200/JCO.2009.25.5729",
      "author": "LA Korde",
      "doi-asserted-by": "publisher",
      "first-page": "2114",
      "journal-title": "J Clin Oncol",
      "key": "1507_CR2",
      "unstructured": "Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28:2114–22.",
      "volume": "28",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.ygyno.2019.01.027",
      "author": "M Suszynska",
      "doi-asserted-by": "publisher",
      "first-page": "452",
      "journal-title": "Gynecol Oncol",
      "key": "1507_CR3",
      "unstructured": "Suszynska M, Klonowska K, Jasinska AJ, Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes — Providing evidence of cancer predisposition genes. Gynecol Oncol. 2019;153:452–62. https://doi.org/10.1016/j.ygyno.2019.01.027.",
      "volume": "153",
      "year": "2019"
    },
    {
      "DOI": "10.1186/s13048-020-00654-3",
      "author": "M Suszynska",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "J Ovarian Res",
      "key": "1507_CR4",
      "unstructured": "Suszynska M, Ratajska M, Kozlowski PBRIP1. RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res. 2020;13:1–11.",
      "volume": "13",
      "year": "2020"
    },
    {
      "DOI": "10.1093/jnci/djw302",
      "author": "KB Kuchenbaecker",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "J Natl Cancer Inst",
      "key": "1507_CR5",
      "unstructured": "Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2017;109:1–15.",
      "volume": "109",
      "year": "2017"
    },
    {
      "DOI": "10.1200/JCO.19.01907",
      "author": "X Yang",
      "doi-asserted-by": "publisher",
      "first-page": "674",
      "journal-title": "J Clin Oncol",
      "key": "1507_CR6",
      "unstructured": "Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020;38:674–85.",
      "volume": "38",
      "year": "2020"
    },
    {
      "DOI": "10.1093/jnci/djaa030",
      "author": "X Yang",
      "doi-asserted-by": "publisher",
      "first-page": "1242",
      "journal-title": "J Natl Cancer Inst",
      "key": "1507_CR7",
      "unstructured": "Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, et al. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. J Natl Cancer Inst. 2020;112:1242–50.",
      "volume": "112",
      "year": "2020"
    },
    {
      "key": "1507_CR8",
      "unstructured": "(NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, v3.2023) (Daly et al. 2022). Genetic / Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. 2022;"
    },
    {
      "DOI": "10.1016/j.ajhg.2018.11.002",
      "author": "N Mavaddat",
      "doi-asserted-by": "publisher",
      "first-page": "21",
      "journal-title": "Am J Hum Genet",
      "key": "1507_CR9",
      "unstructured": "Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 2019;104:21–34.",
      "volume": "104",
      "year": "2019"
    },
    {
      "DOI": "10.1038/s41436-021-01198-7",
      "author": "IMM Lakeman",
      "doi-asserted-by": "publisher",
      "first-page": "1726",
      "journal-title": "Genet Med",
      "key": "1507_CR10",
      "unstructured": "Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, et al. The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med. 2021;23:1726–37.",
      "volume": "23",
      "year": "2021"
    },
    {
      "DOI": "10.1136/jmg-2022-108502",
      "doi-asserted-by": "crossref",
      "key": "1507_CR11",
      "unstructured": "Lakeman IMM, Rodríguez-Girondo MDM, Lee A, Celosse N, Braspenning ME, van Engelen K, et al. Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases. J Med Genet. 2023;60:327–36."
    },
    {
      "DOI": "10.1093/hmg/ddaa136",
      "author": "T Yanes",
      "doi-asserted-by": "publisher",
      "first-page": "R165",
      "journal-title": "Hum Mol Genet",
      "key": "1507_CR12",
      "unstructured": "Yanes T, McInerney-Leo AM, Law MH, Cummings S. The emerging field of polygenic risk scores and perspective for use in clinical care. Hum Mol Genet. 2020;29:R165–76.",
      "volume": "29",
      "year": "2020"
    },
    {
      "author": "N Mavaddat",
      "first-page": "1",
      "journal-title": "JAMA Oncol",
      "key": "1507_CR13",
      "unstructured": "Mavaddat N, Dorling L, Carvalho S, Allen J, González-Neira A, Keeman R, et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 2022;8:1–11.",
      "volume": "8",
      "year": "2022"
    },
    {
      "DOI": "10.1177/1758834017714993",
      "author": "RT Neff",
      "doi-asserted-by": "publisher",
      "first-page": "519",
      "journal-title": "Ther Adv Med Oncol",
      "key": "1507_CR14",
      "unstructured": "Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol. 2017;9:519–31.",
      "volume": "9",
      "year": "2017"
    },
    {
      "DOI": "10.1200/JCO.2011.39.8545",
      "doi-asserted-by": "crossref",
      "key": "1507_CR15",
      "unstructured": "Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group. J Clin Oncol. 2012;30:2654-63."
    },
    {
      "DOI": "10.1038/nature10166",
      "doi-asserted-by": "crossref",
      "key": "1507_CR16",
      "unstructured": "Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature.2011; 474:609-15."
    },
    {
      "DOI": "10.1093/jnci/djz080",
      "author": "JR Vos",
      "doi-asserted-by": "publisher",
      "first-page": "161",
      "journal-title": "J Natl Cancer Inst",
      "key": "1507_CR17",
      "unstructured": "Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, et al. Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition. J Natl Cancer Inst. 2020;112:161–9.",
      "volume": "112",
      "year": "2020"
    },
    {
      "DOI": "10.1155/2014/787143",
      "author": "G Girolimetti",
      "doi-asserted-by": "publisher",
      "first-page": "787143",
      "journal-title": "BioMed Res Int",
      "key": "1507_CR18",
      "unstructured": "Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, et al. BRCA-associated ovarian cancer: From molecular genetics to risk management. BioMed Res Int. 2014;2014:787143.",
      "volume": "2014",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.ejca.2016.10.006",
      "doi-asserted-by": "crossref",
      "key": "1507_CR19",
      "unstructured": "Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016;69:127−34."
    },
    {
      "DOI": "10.1097/PAP.0b013e3182a92cf8",
      "author": "MH Chui",
      "doi-asserted-by": "publisher",
      "first-page": "378",
      "journal-title": "Adv Anat Pathol",
      "key": "1507_CR20",
      "unstructured": "Chui MH, Gilks CB, Cooper K, Clarke BA. Identifying lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. Adv Anat Pathol. 2013;20:378–86.",
      "volume": "20",
      "year": "2013"
    },
    {
      "DOI": "10.1038/s12276-021-00557-3",
      "author": "DS Kim",
      "doi-asserted-by": "publisher",
      "first-page": "42",
      "journal-title": "Exp Mol Med",
      "key": "1507_CR21",
      "unstructured": "Kim DS, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med. 2021;53:42–51. https://doi.org/10.1038/s12276-021-00557-3.",
      "volume": "53",
      "year": "2021"
    },
    {
      "DOI": "10.1186/s12943-019-1085-0",
      "author": "H Li",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Mol Cancer",
      "key": "1507_CR22",
      "unstructured": "Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19:1–16.",
      "volume": "19",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.tcb.2019.07.008",
      "author": "SM Noordermeer",
      "doi-asserted-by": "publisher",
      "first-page": "820",
      "journal-title": "Trends Cell Biol",
      "key": "1507_CR23",
      "unstructured": "Noordermeer SM, van Attikum H. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells. Trends Cell Biol. 2019;29:820–34.",
      "volume": "29",
      "year": "2019"
    },
    {
      "DOI": "10.1038/sj.bjc.6602175",
      "doi-asserted-by": "crossref",
      "key": "1507_CR24",
      "unstructured": "Antoniou AC, Pharoah PPD, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. 2004;1580–90."
    },
    {
      "DOI": "10.1038/s41436-018-0406-9",
      "author": "A Lee",
      "doi-asserted-by": "publisher",
      "first-page": "1708",
      "journal-title": "Genet Med [Internet]",
      "key": "1507_CR25",
      "unstructured": "Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med [Internet]. 2019;21:1708–18. https://doi.org/10.1038/s41436-018-0406-9.",
      "volume": "21",
      "year": "2019"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-104584",
      "doi-asserted-by": "crossref",
      "key": "1507_CR26",
      "unstructured": "Evans DG, Harkness EF, Plaskocinska I, Wallace AJ, Clancy T, Woodward ER, et al. Pathology update to the Manchester Scoring System based on testing in over 4000 families. 2017;674–81."
    },
    {
      "DOI": "10.1200/JCO.2014.59.5728",
      "author": "G Bougeard",
      "doi-asserted-by": "publisher",
      "first-page": "2345",
      "journal-title": "J Clin Oncol",
      "key": "1507_CR27",
      "unstructured": "Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33:2345–52.",
      "volume": "33",
      "year": "2015"
    },
    {
      "DOI": "10.1001/jamanetworkopen.2019.4428",
      "author": "Z Kemp",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "JAMA Netw Open",
      "key": "1507_CR28",
      "unstructured": "Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, et al. Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Netw Open. 2019;2:1–13.",
      "volume": "2",
      "year": "2019"
    },
    {
      "key": "1507_CR29",
      "unstructured": "NICE. National Institute for Health and Care Excellence [NICE] (2013). 2013 [cited 2021 Jun 21]; https://www.nice.org.uk/guidance/cg164."
    },
    {
      "key": "1507_CR30",
      "unstructured": "(NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, v1.2023) (Armstrong et al. 2022). Ovarian cancer Ovarian cancer. 2022;"
    },
    {
      "DOI": "10.1038/ejhg.2010.101",
      "author": "CJ Mattocks",
      "doi-asserted-by": "publisher",
      "first-page": "1276",
      "journal-title": "Eur J Hum Genet",
      "key": "1507_CR31",
      "unstructured": "Mattocks CJ, Morris MA, Matthijs G, Swinnen E, Corveleyn A, Dequeker E, et al. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet. 2010;18:1276–88.",
      "volume": "18",
      "year": "2010"
    },
    {
      "DOI": "10.1007/s10549-016-4038-y",
      "doi-asserted-by": "publisher",
      "key": "1507_CR32",
      "unstructured": "Moran O, Nikitina D, Royer R, Poll A, Metcalfe K, Narod SA, et al. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel. Breast Cancer Res Treat [Internet]. 2017 Jan [cited 2021 May 26];161:135–42. https://doi.org/10.1007/s10549-016-4038-y."
    },
    {
      "DOI": "10.1056/NEJMsr1406261",
      "author": "HL Rehm",
      "doi-asserted-by": "publisher",
      "first-page": "2235",
      "journal-title": "N. Engl J Med",
      "key": "1507_CR33",
      "unstructured": "Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen — The Clinical Genome Resource. N. Engl J Med. 2015;372:2235–42.",
      "volume": "372",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41436-018-0361-5",
      "author": "K Lee",
      "doi-asserted-by": "publisher",
      "first-page": "1497",
      "journal-title": "Genet Med",
      "key": "1507_CR34",
      "unstructured": "Lee K, Seifert BA, Shimelis H, Ghosh R, Crowley SB, Carter NJ, et al. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Genet Med. 2019;21:1497–506. https://doi.org/10.1038/s41436-018-0361-5.",
      "volume": "21",
      "year": "2019"
    },
    {
      "author": "LV Milko",
      "first-page": "987",
      "journal-title": "HHS Public Access",
      "key": "1507_CR35",
      "unstructured": "Milko LV, Funke BH, Hershberger RE, Danielle R, Lee K, Riggs ER, et al. HHS Public Access. 2019;21:987–93.",
      "volume": "21",
      "year": "2019"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-105188",
      "author": "A Taylor",
      "doi-asserted-by": "publisher",
      "first-page": "372",
      "journal-title": "J Med Genet",
      "key": "1507_CR36",
      "unstructured": "Taylor A, Brady AF, Frayling IM, Hanson H, Tischkowitz M, Turnbull C, et al. Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group. J Med Genet. 2018;55:372–7.",
      "volume": "55",
      "year": "2018"
    },
    {
      "DOI": "10.1002/humu.23375",
      "author": "G Ellison",
      "doi-asserted-by": "publisher",
      "first-page": "394",
      "journal-title": "Hum Mutat",
      "key": "1507_CR37",
      "unstructured": "Ellison G, Ahdesmäki M, Luke S, Waring PM, Wallace A, Wright R, et al. An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. Hum Mutat. 2018;39:394–405.",
      "volume": "39",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.jmoldx.2017.07.004",
      "author": "J Kerkhof",
      "doi-asserted-by": "publisher",
      "first-page": "905",
      "journal-title": "J Mol Diagnostics",
      "key": "1507_CR38",
      "unstructured": "Kerkhof J, Schenkel LC, Reilly J, McRobbie S, Aref-Eshghi E, Stuart A, et al. Clinical validation of copy number variant detection from targeted next-generation sequencing panels. J Mol Diagnostics. 2017;19:905–20. https://doi.org/10.1016/j.jmoldx.2017.07.004.",
      "volume": "19",
      "year": "2017"
    },
    {
      "DOI": "10.1186/s12920-018-0466-3",
      "author": "D Mancini-Dinardo",
      "doi-asserted-by": "crossref",
      "first-page": "1",
      "journal-title": "BMC Med Genome",
      "key": "1507_CR39",
      "unstructured": "Mancini-Dinardo D, Judkins T, Kidd J, Bernhisel R, Daniels C, Brown K, et al. Detection of large rearrangements in a hereditary pan-cancer panel using next-generation sequencing. BMC Med Genome. 2019;12:1–9.",
      "volume": "12",
      "year": "2019"
    },
    {
      "DOI": "10.1038/s41436-019-0633-8",
      "author": "H LaDuca",
      "doi-asserted-by": "publisher",
      "first-page": "407",
      "journal-title": "Genet Med",
      "key": "1507_CR40",
      "unstructured": "LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S, Hart SN, et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020;22:407–15.",
      "volume": "22",
      "year": "2020"
    },
    {
      "DOI": "10.1111/1471-0528.16975",
      "author": "B Frugtniet",
      "doi-asserted-by": "publisher",
      "first-page": "433",
      "journal-title": "Int J Obstet Gynaecol",
      "key": "1507_CR41",
      "unstructured": "Frugtniet B, Morgan S, Murray A, Palmer-Smith S, White R, Jones R, et al. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit. BJOG An. Int J Obstet Gynaecol. 2022;129:433–42.",
      "volume": "129",
      "year": "2022"
    },
    {
      "DOI": "10.1001/jamanetworkopen.2020.19452",
      "author": "SE Lincoln",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "JAMA Netw Open",
      "key": "1507_CR42",
      "unstructured": "Lincoln SE, Nussbaum RL, Kurian AW, Nielsen SM, Das K, Michalski S, et al. Yield and utility of germline testing following tumor sequencing in patients with cancer. JAMA Netw Open. 2020;3:1–10.",
      "volume": "3",
      "year": "2020"
    },
    {
      "DOI": "10.3390/diagnostics11030565",
      "author": "A Toss",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Diagnostics",
      "key": "1507_CR43",
      "unstructured": "Toss A, Piombino C, Tenedini E, Bologna A, Gasparini E, Tarantino V, et al. The prognostic and predictive role of somatic brca mutations in ovarian cancer: Results from a multicenter cohort study. Diagnostics 2021;11:1–15.",
      "volume": "11",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.annonc.2022.12.003",
      "author": "Z Kuzbari",
      "doi-asserted-by": "publisher",
      "first-page": "215",
      "journal-title": "Ann Oncol",
      "key": "1507_CR44",
      "unstructured": "Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, George A, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol. 2023;34:215–27. https://doi.org/10.1016/j.annonc.2022.12.003.",
      "volume": "34",
      "year": "2023"
    },
    {
      "DOI": "10.1016/j.modpat.2022.100049",
      "author": "KD Doig",
      "doi-asserted-by": "publisher",
      "first-page": "100049",
      "journal-title": "Mod Pathol",
      "key": "1507_CR45",
      "unstructured": "Doig KD, Fellowes AP, Fox SB. Homologous recombination repair deficiency: an overview for pathologists. Mod Pathol. 2023;36:100049. https://doi.org/10.1016/j.modpat.2022.100049.",
      "volume": "36",
      "year": "2023"
    },
    {
      "DOI": "10.1038/s41431-021-00817-w",
      "author": "S Bennett",
      "doi-asserted-by": "publisher",
      "first-page": "861",
      "journal-title": "Eur J Hum Genet",
      "key": "1507_CR46",
      "unstructured": "Bennett S, Alexander E, Fraser H, Bowers N, Wallace A, Woodward ER, et al. Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives. Eur J Hum Genet. 2021;29:861–71. https://doi.org/10.1038/s41431-021-00817-w.",
      "volume": "29",
      "year": "2021"
    },
    {
      "DOI": "10.1002/humu.20880",
      "author": "SE Plon",
      "doi-asserted-by": "publisher",
      "first-page": "1282",
      "journal-title": "Hum Mutat",
      "key": "1507_CR47",
      "unstructured": "Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–91.",
      "volume": "29",
      "year": "2008"
    },
    {
      "DOI": "10.1038/gim.2015.30",
      "doi-asserted-by": "crossref",
      "key": "1507_CR48",
      "unstructured": "Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. 2015; www.lrg-sequence.org."
    },
    {
      "DOI": "10.1101/531210",
      "doi-asserted-by": "publisher",
      "key": "1507_CR49",
      "unstructured": "Ellard S, Baple EL, Callaway A, Berry I, Forrester N, Turnbull C, et al. ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2020 Recommendations ratified by ACGS Quality Subcommittee on 4th. 2020 [cited 2020 Nov 3]; Available from: https://doi.org/10.1101/531210."
    },
    {
      "DOI": "10.1136/jmedgenet-2019-106759",
      "author": "A Garrett",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "J Med Genet",
      "key": "1507_CR50",
      "unstructured": "Garrett A, Callaway A, Durkie M, Cubuk C, Alikian M, Burghel GJ, et al. Cancer variant interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network. J Med Genet. 2020;57:1–6.",
      "volume": "57",
      "year": "2020"
    },
    {
      "DOI": "10.1186/s13073-022-01073-3",
      "author": "JM Ellingford",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Genome Med",
      "key": "1507_CR51",
      "unstructured": "Ellingford JM, Ahn JW, Bagnall RD, Baralle D, Barton S, Campbell C, et al. Recommendations for clinical interpretation of variants found in non-coding regions of the genome. Genome Med. 2022;14:1–19. https://doi.org/10.1186/s13073-022-01073-3.",
      "volume": "14",
      "year": "2022"
    },
    {
      "DOI": "10.1016/j.gim.2022.01.001",
      "author": "P Horak",
      "doi-asserted-by": "publisher",
      "first-page": "986",
      "journal-title": "Genet Med",
      "key": "1507_CR52",
      "unstructured": "Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022;24:986–98.",
      "volume": "24",
      "year": "2022"
    },
    {
      "DOI": "10.1093/annonc/mdz136",
      "author": "D Mandelker",
      "doi-asserted-by": "publisher",
      "first-page": "1221",
      "journal-title": "Ann Oncol",
      "key": "1507_CR53",
      "unstructured": "Mandelker D, Donoghue M, Talukdar S, Bandlamudi C, Srinivasan P, Vivek M, et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2019;30:1221–31. https://doi.org/10.1093/annonc/mdz136.",
      "volume": "30",
      "year": "2019"
    },
    {
      "DOI": "10.1093/nar/gkx1153",
      "author": "MJ Landrum",
      "doi-asserted-by": "publisher",
      "first-page": "D1062",
      "journal-title": "Nucleic Acids Res",
      "key": "1507_CR54",
      "unstructured": "Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062–7.",
      "volume": "46",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.gim.2021.11.011",
      "author": "L Loong",
      "doi-asserted-by": "publisher",
      "first-page": "552",
      "journal-title": "Genet Med",
      "key": "1507_CR55",
      "unstructured": "Loong L, Cubuk C, Choi S, Allen S, Torr B, Garrett A, et al. Quantifying prediction of pathogenicity for within-codon concordance (PM5) using 7541 functional classifications of BRCA1 and MSH2 missense variants. Genet Med. 2022;24:552–63.",
      "volume": "24",
      "year": "2022"
    },
    {
      "DOI": "10.1002/humu.23406",
      "author": "TR Rebbeck",
      "doi-asserted-by": "publisher",
      "first-page": "593",
      "journal-title": "Hum Mutat",
      "key": "1507_CR56",
      "unstructured": "Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018;39:593–620.",
      "volume": "39",
      "year": "2018"
    },
    {
      "DOI": "10.1038/s41436-018-0052-2",
      "author": "RLS Mesman",
      "doi-asserted-by": "publisher",
      "first-page": "293",
      "journal-title": "Genet Med",
      "key": "1507_CR57",
      "unstructured": "Mesman RLS, Calléja FMGR, Hendriks G, Morolli B, Misovic B, Devilee P, et al. The functional impact of variants of uncertain significance in BRCA2. Genet Med. 2019;21:293–302. https://doi.org/10.1038/s41436-018-0052-2.",
      "volume": "21",
      "year": "2019"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-104560",
      "author": "S Moghadasi",
      "doi-asserted-by": "publisher",
      "first-page": "15",
      "journal-title": "J Med Genet",
      "key": "1507_CR58",
      "unstructured": "Moghadasi S, Meeks HD, Vreeswijk PM, Janssen LAM, Borg Å, Ehrencrona H, et al. The BRCA1 c. 5096 G \u003e A p.Arg1699Gln (R1699Q) intermediate risk variant: Breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. J Med Genet. 2018;55:15–20.",
      "volume": "55",
      "year": "2018"
    },
    {
      "DOI": "10.1186/s13073-022-01052-8",
      "author": "L Dorling",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Genome Med",
      "key": "1507_CR59",
      "unstructured": "Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, González-Neira A, et al. Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Med. 2022;14:1–17. https://doi.org/10.1186/s13073-022-01052-8.",
      "volume": "14",
      "year": "2022"
    },
    {
      "DOI": "10.1007/s10689-020-00207-z",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Fam Cancer",
      "key": "1507_CR60",
      "unstructured": "Evans DG, Woodward ER. New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer. Fam Cancer. 2021;20:1–7. https://doi.org/10.1007/s10689-020-00207-z.",
      "volume": "20",
      "year": "2021"
    },
    {
      "DOI": "10.1200/PO.21.00278",
      "author": "AN Schwartz",
      "doi-asserted-by": "publisher",
      "first-page": "1677",
      "journal-title": "JCO Precis Oncol",
      "key": "1507_CR61",
      "unstructured": "Schwartz AN, Hyman SR, Stokes SM, Castillo D, Tung NM, Weitzel JN. et al. Evaluation of TP53 variants detected on peripheral blood or saliva testing: discerning germline from somatic TP53 variants. JCO Precis Oncol. 2021;5:1677–86.",
      "volume": "5",
      "year": "2021"
    },
    {
      "DOI": "10.1038/s41431-022-01091-0",
      "author": "ZC Deans",
      "doi-asserted-by": "publisher",
      "first-page": "1011",
      "journal-title": "Eur J Hum Genet",
      "key": "1507_CR62",
      "unstructured": "Deans ZC, Ahn JW, Carreira IM, Dequeker E, Henderson M, Lovrecic L, et al. Recommendations for reporting results of diagnostic genomic testing. Eur J Hum Genet. 2022;30:1011–6.",
      "volume": "30",
      "year": "2022"
    },
    {
      "key": "1507_CR63",
      "unstructured": "Cresswell L, Wallis Y, Fews G, Deans Z, Fratter C, Monkman L, et al. General Genetic Laboratory Reporting Recommendations Version 1.1. Recommendations ratified by ACGS Quality Subcommittee on 24/02/20). Available from: https://www.acgs.uk.com/quality/best-practice-guidelines/."
    },
    {
      "key": "1507_CR64",
      "unstructured": "Deans Z, Watson CM, Charlton R, Ellard S, Wallis Y, Mattocks C, et al. Practice guidelines for targeted next generation sequencing analysis and interpretation [Internet]. 2015 [cited 2020 Nov 3]. https://sites.stanford.edu/abms/giab."
    },
    {
      "key": "1507_CR65",
      "unstructured": "Ellard S, Charlton R, Yau S, Gokhale D, Taylor GR, Wallace A, et al. Practice guidelines for sanger sequencing analysis and interpretation [Internet]. 2016 [cited 2020 Nov 3]. www.repeatmasker.org/."
    },
    {
      "DOI": "10.1038/s41586-022-04558-8",
      "author": "J Morales",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Nature",
      "key": "1507_CR66",
      "unstructured": "Morales J, Pujar S, Loveland JE, Astashyn A, Bennett R, Berry A, et al. A joint NCBI and EMBL-EBI transcript set for clinical genomics and research. Nature. 2022;604:1–6. https://doi.org/10.1038/s41586-022-04558-8.",
      "volume": "604",
      "year": "2022"
    },
    {
      "DOI": "10.1136/jclinpath-2014-202404",
      "author": "IA Cree",
      "doi-asserted-by": "publisher",
      "first-page": "923",
      "journal-title": "J Clin Pathol",
      "key": "1507_CR67",
      "unstructured": "Cree IA, Cree IA, Deans Z, Ligtenberg MJL, Groenen P, Van Krieken JH, et al. Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014;67:923–31.",
      "volume": "67",
      "year": "2014"
    },
    {
      "DOI": "10.1200/JCO.19.02960",
      "author": "PA Konstantinopoulos",
      "doi-asserted-by": "publisher",
      "first-page": "1222",
      "journal-title": "J Clin Oncol",
      "key": "1507_CR68",
      "unstructured": "Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38:1222–45.",
      "volume": "38",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.jmoldx.2016.10.002",
      "author": "MM Li",
      "doi-asserted-by": "publisher",
      "first-page": "4",
      "journal-title": "J Mol Diagnostics",
      "key": "1507_CR69",
      "unstructured": "Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagnostics. 2017;19:4–23. https://doi.org/10.1016/j.jmoldx.2016.10.002.",
      "volume": "19",
      "year": "2017"
    }
  ],
  "reference-count": 69,
  "references-count": 69,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41431-023-01507-5"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy"
}